An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer

Trial Profile

An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Panitumumab (Primary) ; Cisplatin; Fluorouracil
  • Indications Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms POWER
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 According to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology the Status changed from active, no longer recruiting to discontinued after the interim analysis for futility
    • 20 Jan 2017 Planned End Date changed from 1 Sep 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top